Pivotal bioVenture Partners Fund I, L.P. - 31 Dec 2025 SCHEDULE 13G Report for Evommune, Inc. Common Stock, par value $0.0001 per share (EVMN)

Filing manager
Pivotal bioVenture Partners Fund I, L.P.
Reporting owner
Nan Fung Group Holdings Limited
Security
Evommune, Inc. Common Stock, par value $0.0001 per share
Beneficially owned shares
3,435,599 shares
Ownership signal CIK-linked ownership evidence from parsed SEC filings. 2 signals
Large-stake signal

Form

SCHEDULE 13G

Passive or exempt beneficial ownership filing.

Ownership

11%

Beneficial ownership of this reported class.

Shares

3,435,599 shares

Shares beneficially owned as disclosed.

Event date

31 Dec 2025

Date tied to the ownership event or amendment.

Accepted by SEC

13 Feb 2026

EDGAR acceptance date.

How to read this large-stake filing
  • Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
  • Compare this filing with the holder history and issuer page before treating the percentage as a current position.
  • Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
Class ownership
11%
Subject security Names, identifiers, and filing context for this profile. 2 source fields
Symbol
EVMN
Shares outstanding
31,519,257 shares
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
SCHEDULE 13G
Accepted by SEC
13 Feb 2026, 16:10:03 UTC
Event date
31 Dec 2025
Source filing
View source filing

Key filing fact

Pivotal bioVenture Partners Fund I, L.P. disclosed 11% ownership in Evommune, Inc. Common Stock, par value $0.0001 per share (EVMN) on 31 Dec 2025.

Key facts

  • Pivotal bioVenture Partners Fund I, L.P. filed SCHEDULE 13G for Evommune, Inc. Common Stock, par value $0.0001 per share (EVMN).
  • Disclosed ownership: 11%.
  • Date of event: 31 Dec 2025.

Change

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 13 Feb 2026, 16:10.

Research use

  • This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
  • Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.

Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

View source filing

Reporting persons

Disclosed reporting parties (13)

Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.

Name Ownership Shares owned Sole voting power Shared voting power Signature Title CIK
Nan Fung Group Holdings Limited 11% 3,435,599 0 3,435,599 /s/ Tang Chun Wai Nelson Tang Chun Wai Nelson, Director
NF Investment Holdings Limited 11% 3,367,975 0 3,367,975 /s/ Tang Chun Wai Nelson Tang Chun Wai Nelson, Director
Nan Fung Life Sciences Holdings Limited 11% 3,367,975 0 3,367,975 /s/ Sun Xintong Sun Xintong, Director
NFLS Platform Holdings Limited 4.6% 1,441,032 0 1,441,032 /s/ Sun Xintong Sun Xintong, Director
NFLS Delta III Limited 4.6% 1,441,032 0 1,441,032 /s/ Sun Xintong Sun Xintong, Director
Pivotal Life Sciences Holdings Limited 6.1% 1,926,943 0 1,926,943 /s/ Sun Xintong Sun Xintong, Director
Pivotal Partners Ltd 6.1% 1,926,943 0 1,926,943 /s/ Sun Xintong Sun Xintong, Director
Pivotal bioVenture Partners Fund I U.G.P. Ltd. 5.2% 1,632,441 0 1,632,441 /s/ Robert Hopfner Robert Hopfner, Authorized Signatory
Pivotal bioVenture Partners Fund I G.P., L.P. 5.2% 1,632,441 0 1,632,441 /s/ Robert Hopfner By: Pivotal bioVenture Partners Fund I U.G.P. Ltd., its general partner; By: Robert Hopfner, Authorized Signatory
Pivotal bioVenture Partners Fund I, L.P. 5.2% 1,632,441 0 1,632,441 Pivotal bioVenture Partners Fund I G.P., L.P. its general partner
Pivotal bioVenture Partners Fund II G.P. Ltd 0.9% 294,502 0 294,502 /s/ Peter Tuxen Bisgaard By: Peter Tuxen Bisgaard, Director
Pivotal bioVenture Partners Fund II, L.P. 0.9% 294,502 0 294,502 Pivotal bioVenture Partners Fund II G.P. Ltd its general partner
NFLS Delta Limited 4.6% 1,441,032 0 1,441,032 /s/ Sun Xintong Sun Xintong, Director
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .